Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
Relevant for
FixVUE, InSituPlex, U-VUE
Description Overview highlighting the use of the InSituPlex® (ISP) a novel, robust mIF assay technology reliant on conjugating DNA barcodes to antibodies and using sequence-specific DNA-DNA hybridization tolabel antibodies for spatial profiling of immuno-oncology targets in FFPE tumor tissue
Senior Field Applications Scientist, Ultivue
Relevant for
FixVUE, InSituPlex
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
Associate Director, Scientific Affairs; Senior Scientist, Visiopharm
Relevant for
Collaboration, FixVUE, InSituPlex
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
Dr. Fabian Schneider is part of Visiopharm’s R&D and Product Management team, responsible for phenotyping products as well as service projects for custom APP development. Fabian has over 10 years of international experience in cancer biology and immuno-oncology, working in academic research labs, clinical research teams and computational pathology groups in both academia and biopharma. Fabian received his Dr phil. nat. in Cell Biology in 2011 from the Johan Wolfgang Goethe University Frankfurt, Germany.
Relevant for
Collaboration, FixVUE, InSituPlex
Description We describe the potential of accurate cellular phenotyping using the InSituPlex technology with fast whole-slide scanning using ZEISS Axioscan 7, an automated slide scanning system for fluorescence and transmitted light applications with modern cameras, a sophisticated focusing method and a powerful imaging software. The compounded effect of integrating these technologies can significantly improve the throughput of immuno-oncology research.
Catherine Benson, Keith Wharton, Gourab Chatterjee, Markus Neumann, Volker Döring and Maël Manesse
Presented at: AACR 2021
Relevant for
Collaboration, FixVUE, InSituPlex
Description Understanding the complexities of the tumor micro-environment in detail can vastly improve the accuracy of immuno-oncology research and accelerate the discovery of potential immunotherapy targets. Multiplexed immunofluorescence (mIF) assays have emerged as a critical approach for identifying complex cellular phenotypes in the tumor micro-environment, powered by the value of the spatial correlation of such phenotypes in a tissue specimen. Although many methods for multiplexed IF exist, they are often costly and require time-consuming assay development and long imaging times. The Ultivue UltiMapper kits enable rapid, pre-optimized staining of multiple targets simultaneously in a single FFPE tissue section. This technology is ready-to-use with conventional automated staining workflows and commercially available automated imaging systems. Here, we demonstrate the potential of accurate cellular phenotyping using the InSituPlex technology with fast whole-slide scanning using ZEISS Axioscan.Z1 an automated slide scanning system for fluorescence and transmitted light applications with modern cameras, a sophisticated focusing method and a powerful imaging software. The compounded effect of integrating these technologies can significantly improve the throughput of immuno-oncology research. A 4-target immunostaining assay was performed on multiple FFPE tumor sections using UltiMapper reagents. Briefly, slides were stained with a cocktail of primary antibodies using a Leica Biosystems BOND RX autostainer. Post-staining, the slides were coverslipped and imaged on ZEISS Axioscan.Z1. The resulting images were analyzed using IndicaLabs HALO analysis software. In this poster, we report on an efficient and streamlined workflow for mIF staining, imaging, and analysis of tumor samples. After nuclear segmentation of the resulting images, T-cell and macrophage populations were subtyped and identified through spatial identification of relevant biomarkers. The combined workflow presented here allows a user to get 4-plex, whole slide immunofluorescence images of FFPE tumor tissues within 6 hours. The automated whole slide scanning capability of ZEISS Axioscan.Z1 also allows a user to image up to 100 slides with minimal external input. The combination of optimized, fast staining UltiMapper reagents with ZEISS Axioscan.Z1 automated whole-slide fluorescence scanner enables rapid, deep immunoprofiling within the spatial context of the tumor, empowering translational and immuno-oncology research.
Catherine Benson, Keith Wharton, Gourab Chatterjee, Markus Neumann, Volker Döring and Maël Manesse
Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
Marie Cumberbatch, Douglas Wood, Christopher Womack, Milan Bhagat, Angela Vasaturo, Mael Manesse and Lorcan Sherry (TriStar, OracleBio)
Relevant for
FixVUE, FlexVUE, InSituPlex, U-VUE
Description Overview highlighting the use of the InSituPlex® (ISP) a novel, robust mIF assay technology reliant on conjugating DNA barcodes to antibodies and using sequence-specific DNA-DNA hybridization tolabel antibodies for spatial profiling of immuno-oncology targets in FFPE tumor tissue
Associate Director Scientific Affairs, Ultivue; Dept of Medical Oncology, University Hospital Brussels
Relevant for
FixVUE, InSituPlex
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
Associate Director, Scientific Affairs Ultivue ;Tissue Hybridization Scientific Lead, Queens University Belfast
Relevant for
FixVUE, InSituPlex
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
At Queens University Belfast, Matt is the Scientific Lead for Tissue Hybridization and Digital Pathology in the Precision Medicine Centre of Excellence. Matt is responsible for the TH&DP team. Their remit was to deliver academic research studies, clinical trials, and industry projects within the PMC.
Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
Presented at: AACR 2020
Relevant for
FixVUE, InSituPlex
Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
InSituPlex
5818
Design and application of an 8-plex multiplex immunofluorescence panel for deep phenotypic profiling of the tumor microenvironment using InSituPlex technology
